Natera Inc. is asking the patent review board to invalidate an Illumina Inc. genetic testing patent after a court refused to do so last week.
Natera, based in San Carlos, Calif., offers genetic testing services, including several reproductive health offerings. Illumina has alleged in district court that Natera’s Panorama test for Down syndrome and other genetic conditions infringes one of its patents. Now Natera is hoping the Patent Trial and Appeal Board will find U.S. Patent No. 9,493,831 isn’t patentable.
Natera’s PTAB petition is an example of a typical tactic alleged patent infringers take that has led to calls to ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.